Finance-Funding

  1. Milestone Payments In Life Sciences M&A And Licensing Transactions 7/1/2022

    Now is an opportune time to take a fresh look at some key considerations regarding a common feature of M&As — payments that become due in the future upon the achievement of specified events, which are commonly known as “milestones.”

  2. Key Considerations In Early-Stage Biopharma Financing 5/2/2022

    After over two years of soaring IPO valuations and high stock prices, biotech had a reckoning in the back half of 2021.

  3. Is Biopharma Poised For Bigger Deals In 2022? 5/2/2022

    Biopharma companies are sitting on roughly $1.2 trillion in firepower, according to a recent report by Ernst & Young. But firepower to spend on deals — which includes cash, existing debt, and market capitalization — won’t necessarily translate into multibillion-dollar transactions, at least in the short term.

  4. Embracing Challenges And Executing A Successful IPO 5/2/2022

    John Jacobs, CEO of Harmony Biosciences, discusses the challenges and lessons learned from when his company transitioned from private to public.

  5. A Q&A With A Venture Capitalist/Genetic Medicines Executive 4/1/2022

    Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good story is the first step.

  6. Why Biotechs Need A Practical Approach To Going Public 3/1/2022

    Biotechs, in particular, should be mindful of the ramifications of the avenue they choose to go public. Here’s a look at three options and their challenges.

  7. Turbocharging Early-Stage Biotech Growth With Venture Debt 11/1/2021

    A growing number of early-stage companies are making strategic use of venture-debt financing to cover short-term cash needs, providing a longer cash runway that helps cover ongoing costs of product development and commercialization without diluting equity.

  8. Why It’s Never Too Early To Develop Your Exit Strategy 10/1/2021

    It’s important to consider an exit strategy early in your process instead of waiting until there are challenges with liquidity, profitability, efficiency, lack of succession planning, and different partner expectations that would call for you to exit.

  9. Gearing Up For A Biotech M&A Boom 10/1/2021

    Biotech M&A was slow in the first half of 2021, but that may be changing, with emerging trends indicating that a biotech M&A boom could be on the horizon. If your biotech is hoping to be acquired by a larger pharma company, it’s crucial that you start preparing now.

  10. VCs Breathe New Life Into Life Sciences Industrials 9/1/2021

    The “industrials” or supplier sector of the biopharma industry, in a significant change from the past, is now receiving an extra financial boost from VC funding. Why should their biopharma customers care?